An Open-Label, Dose Escalation Phase I Trial of MK-0646 Given as a One to Two Hour Every Other Week Infusion in Patients With Relapsed or Refractory Locally Advanced or Metastatic Cancers
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Dalotuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme
- 22 Jan 2009 Actual initiation date changed from Sep 2006 to Jul 2006 as reported by ClinicalTrials.gov.
- 12 Jan 2009 Actual initiation date (Sep 2006) added as reported by ClinicalTrials.gov.
- 12 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.